http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2625118-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34bd4e87ecbca17f16d460ca394e60f9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38 |
| filingDate | 1976-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca1ecfe32fb9adcce70118991d945bcb |
| publicationDate | 1977-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-2625118-A1 |
| titleOfInvention | DRUG |
| abstract | (A) Pharmaceutical compsns. contain as active ingredient >=1 pyrimidine derivs. of formula (I) and and/or their pharmaceutically acceptable salts: (X is N or R2-C triple bond; R is H, a pharmaceutically acceptable cation or 1-5C alkyl; R1 and R2 are H, 1-5C alkyl, aralkyl, phenyl, thienyl or pyridyl, opt. substd. by halo, or 1-4C alkyl or alkyloxy, or they are 5-7C cycloalkyl). (I) are new cpds. provided that (a) when R1 is H and X is R2C triple bond, then R2 is not H or CH3, and (b) when X is N, R1 is not CH3. (I) stimulate the body's natural defence mechanisms so are useful in treating bacterial or viral diseases, acute diseminated lupuserhthematus and tumours (esp. to prevent appearance of metastases). The usual oral dose is 25-500 mg; they can also be given reactally, by injection or as nasal sprays. |
| priorityDate | 1976-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.